Adjuvant therapy for melanoma: how to choose?
- PMID: 32007137
- DOI: 10.1016/S1470-2045(20)30002-4
Adjuvant therapy for melanoma: how to choose?
Comment on
-
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.Lancet Oncol. 2020 Mar;21(3):358-372. doi: 10.1016/S1470-2045(20)30062-0. Epub 2020 Jan 30. Lancet Oncol. 2020. PMID: 32007138 Clinical Trial.
Similar articles
-
Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma.N Engl J Med. 2019 Apr 4;380(14):1374-1376. doi: 10.1056/NEJMc1902228. N Engl J Med. 2019. PMID: 30943345 No abstract available.
-
What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma?J Clin Oncol. 2019 May 20;37(15):1355-1356. doi: 10.1200/JCO.18.02075. Epub 2019 Apr 2. J Clin Oncol. 2019. PMID: 30939094 No abstract available.
-
Beneficial Effect of Adjuvant Dabrafenib Plus Trametinib on Recurrence-Free Survival in Patients With Resected BRAFV600-Mutant Stage III Melanoma Seems to be Short-Lived.J Clin Oncol. 2019 May 20;37(15):1354-1355. doi: 10.1200/JCO.18.01768. Epub 2019 Apr 2. J Clin Oncol. 2019. PMID: 30939097 Free PMC article. No abstract available.
-
Current systemic therapies for melanoma.Dermatol Surg. 2014 Sep;40(9):948-63. doi: 10.1097/01.DSS.0000452626.09513.55. Dermatol Surg. 2014. PMID: 25072125 Review.
-
[Treatment of BRAF-mutated metastatic melanoma].Ugeskr Laeger. 2016 Aug 29;178(35):V02160126. Ugeskr Laeger. 2016. PMID: 27592869 Review. Danish.
Cited by
-
Metformin Increases Sensitivity of Melanoma Cells to Cisplatin by Blocking Exosomal-Mediated miR-34a Secretion.J Oncol. 2021 Nov 29;2021:5525231. doi: 10.1155/2021/5525231. eCollection 2021. J Oncol. 2021. PMID: 34880915 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical